Oncolytic Vaccinia Virus in Lung Cancer Vaccines

Oncolytic Vaccinia Virus in Lung Cancer Vaccines

Therapeutic cancer vaccines represent a promising therapeutic modality via the induction of long-term immune response and reduction in adverse effects by specifically targeting tumor-associated antigens. Oncolytic virus, especially vaccinia virus (VV) is a promising cancer treatment option for effec...

Full description

Bibliographic Details
Main Authors:	Cao-Sang Truong, So Young Yoo
Format:	Article
Language:	English
Published:	MDPI AG 2022-02-01
Series:	Vaccines
Subjects:	vaccinia virus oncolytic virus non-small cell lung cancer cancer vaccine immunotherapy personalized vaccination
Online Access:	https://www.mdpi.com/2076-393X/10/2/240

Similar Items

Recent progress in combination therapy of oncolytic vaccinia virus
by: Seyedeh Nasim Mirbahari, et al.
Published: (2024-03-01)

Oncolytic vaccinia virus and cancer immunotherapy
by: Lihua Xu, et al.
Published: (2024-01-01)

The employment of vaccinia virus for colorectal cancer treatment: A review of preclinical and clinical studies
by: Qiaoyun Ling, et al.
Published: (2022-11-01)

A vaccinia virus renaissance<subtitle>New vaccine and immunotherapeutic uses after smallpox eradication</subtitle>
by: Paulo H. Verardi, et al.
Published: (2012-07-01)

Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti‐tumor immunity with superior safety in bladder cancer models
by: Kyle G Potts, et al.
Published: (2017-03-01)

Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
by: Mengyuan Li, et al.
Published: (2023-09-01)

Vaccinia virus-based vector against infectious diseases and tumors
by: Ziling Zhang, et al.
Published: (2021-06-01)

In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV
by: Nusrat Jahan, et al.
Published: (2021-08-01)

A Comparative Study of Oncolytic Vaccinia Viruses Harboring Different Marine Lectins in Breast Cancer Cells
by: Yanrong Zhou, et al.
Published: (2023-01-01)

Dose Considerations for Vaccinia Oncolytic Virus Based on Retrospective Reanalysis of Early and Late Clinical Trials
by: Mefotse Saha Cyrelle Ornella, et al.
Published: (2024-09-01)

pH Sensitive Erythrocyte-Derived Membrane for Acute Systemic Retention and Increased Infectivity of Coated Oncolytic Vaccinia Virus
by: Kaelan T. Samoranos, et al.
Published: (2022-08-01)

Design Strategies and Precautions for Using Vaccinia Virus in Tumor Virotherapy
by: Xinjun Liu, et al.
Published: (2022-09-01)

Construction of three strains of recombinant oncolytic vaccinia virus and their anti-tumor activity
by: LI Dan-yang, FANG Jing-jing, TANG Hui
Published: (2020-04-01)

Oncolytic Virus Engineering and Utilizations: Cancer Immunotherapy Perspective
by: Palaniyandi Muthukutty, et al.
Published: (2023-07-01)

Oncolytic Viruses in Ovarian Cancer: Where Do We Stand? A Narrative Review
by: Fulvio Borella, et al.
Published: (2025-02-01)

Mediation of antitumor activity by AZD4820 oncolytic vaccinia virus encoding IL-12
by: Cheyne Kurokawa, et al.
Published: (2024-03-01)

A novel oncolytic Vaccinia virus armed with IL-12 augments antitumor immune responses leading to durable regression in murine models of lung cancer
by: Lijuan Chen, et al.
Published: (2025-01-01)

Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment
by: Jee Soo Park, et al.
Published: (2022-01-01)

Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
by: Franck Gallardo, et al.
Published: (2020-11-01)

Neutrophils in oncolytic virus immunotherapy
by: Danya Zhou, et al.
Published: (2024-12-01)

ROS Induced by <i>Aphrocallistes vastus</i> Lectin Enhance Oncolytic Vaccinia Virus Replication and Induce Apoptosis in Hepatocellular Carcinoma Cells
by: Yanan Zhang, et al.
Published: (2024-06-01)

Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
by: Andrea Vannini, et al.
Published: (2023-05-01)

Oncolytics, Cancer-Fighting Viruses from Past to Future: A Literature Review
by: Seyedeh Nasim Mirbahari, et al.
Published: (2024-03-01)

Exploring computational approaches to design mRNA Vaccine against vaccinia and Mpox viruses
by: Elijah K. Oladipo, et al.
Published: (2024-08-01)

Corrigendum: Innovative retargeted oncolytic herpesvirus against nectin4-positive cancers
by: Andrea Vannini, et al.
Published: (2024-06-01)

GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer
by: Yujing Xuan, et al.
Published: (2025-01-01)

Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment
by: So Young Yoo, et al.
Published: (2020-06-01)

Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy
by: Alberto Reale, et al.
Published: (2021-12-01)

Establishing a New Platform to Investigate the Efficacy of Oncolytic Virotherapy in a Human Ex Vivo Peritoneal Carcinomatosis Model
by: Jana Koch, et al.
Published: (2023-01-01)

Oncolytic Virotherapy for Cancer: Clinical Experience
by: Shyambabu Chaurasiya, et al.
Published: (2021-04-01)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Lior Nave, et al.
Published: (2023-08-01)

Enhancing cancer therapy: the integration of oncolytic virus therapy with diverse treatments
by: Zhuo Yan, et al.
Published: (2024-07-01)

Oncolytic Vaccinia Virus Expressing White-Spotted Charr Lectin Regulates Antiviral Response in Tumor Cells and Inhibits Tumor Growth In Vitro and In Vivo
by: Xue Wang, et al.
Published: (2021-05-01)

Effect of the Route of Administration of the Vaccinia Virus Strain LIVP to Mice on Its Virulence and Immunogenicity
by: Sergei N. Shchelkunov, et al.
Published: (2020-07-01)

Strategies for engineering oncolytic viruses to enhance cancer immunotherapy
by: Ziyang (Steve) Yin, et al.
Published: (2024-09-01)

Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice
by: Hajime Kurosaki, et al.
Published: (2021-04-01)

Design and Engineering of Deimmunized Vaccinia Viral Vectors
by: Kevin Song, et al.
Published: (2020-11-01)

Prophylactic Vaccination and Intratumoral Boost with HER2-Expressing Oncolytic Herpes Simplex Virus Induces Robust and Persistent Immune Response against HER2-Positive Tumor Cells
by: Zahid Delwar, et al.
Published: (2023-12-01)

Vaccinia-Virus-Based Vaccines Are Expected to Elicit Highly Cross-Reactive Immunity to the 2022 Monkeypox Virus
by: Syed Faraz Ahmed, et al.
Published: (2022-09-01)

SELECTED ASPECTS OF ALLO- AND XENOGRAFT MODEL APPLICATIONS FOR DEVELOPING NOVEL ANTI-CANCER VACCINES AND ONCOLYTIC VIRUSES
by: T. S. Nepomnyashchikh, et al.
Published: (2019-05-01)